--- title: "早盤趨勢｜海西新藥高位反覆，醫藥龍頭板塊承壓？" description: "海西新藥（2637.HK）近日處於階段高位反覆震盪，資金嘗試拉昇但欠缺力度，顯示主力資金意願分化。醫藥板塊年內持續進行估值修復，板塊龍頭因避險屬性吸引了機構增加配置。近期主流企業密集發佈季度業績預增公告，引發醫藥分支概念二線品種同步走強，不過頭部標的如海西新藥在高位區間放量不配合，量價背離愈發突出。" type: "news" locale: "zh-HK" url: "https://longbridge.com/zh-HK/news/271759883.md" published_at: "2026-01-08T01:00:00.000Z" --- # 早盤趨勢｜海西新藥高位反覆，醫藥龍頭板塊承壓？ > 海西新藥（2637.HK）近日處於階段高位反覆震盪，資金嘗試拉昇但欠缺力度，顯示主力資金意願分化。醫藥板塊年內持續進行估值修復，板塊龍頭因避險屬性吸引了機構增加配置。近期主流企業密集發佈季度業績預增公告，引發醫藥分支概念二線品種同步走強，不過頭部標的如海西新藥在高位區間放量不配合，量價背離愈發突出。 海西新藥（2637.HK）近日處於階段高位反覆震盪，資金嘗試拉昇但欠缺力度，顯示主力資金意願分化。醫藥板塊年內持續進行估值修復，板塊龍頭因避險屬性吸引了機構增加配置。近期主流企業密集發佈季度業績預增公告，引發醫藥分支概念二線品種同步走強，不過頭部標的如海西新藥在高位區間放量不配合，量價背離愈發突出。 技術形態上，海西新藥 K 線處於多頭趨勢中，但高位區反覆未能有效突破，MACD 雖維持多頭但動能明顯放緩。短線資金興趣有限，主要以觀望為主，盤中反彈多為弱勢上探，成交量未同步放大限制後續突破空間。當前市場消息缺乏實質性催化，行業仍在消化此前政策和盈利公告的影響。若後續板塊資金分流，海西新藥回調風險隨之加劇。投資者需關注分時量價變化，識別主力進出意圖，同時跟蹤整體醫療健康板塊情緒邊際波動。穩健策略以迴避高位追漲、降低風險敞口為主，控制倉位兼顧週期性調整的潛在衝擊。 ### Related Stocks - [02637.HK - 海西新藥](https://longbridge.com/zh-HK/quote/02637.HK.md) ## Related News & Research | Title | Description | URL | |-------|-------------|-----| | Guotai Haitong Remains a Buy on Zai Lab Ltd (1ZLB) | Guotai Haitong analyst maintained a Buy rating on Zai Lab Ltd yesterday and set a price target of HK$27.94.Claim 50% Off | [Link](https://longbridge.com/zh-HK/news/277338249.md) | | Shanghai XNG Terminates HK$12 Million Share Placement | Shanghai XNG Terminates HK$12 Million Share Placement | [Link](https://longbridge.com/zh-HK/news/277392488.md) | | Suzhou Ribo Life Science's Cholesterol Medicine to Begin Phase 3 Trial | Suzhou Ribo Life Science's Cholesterol Medicine to Begin Phase 3 Trial | [Link](https://longbridge.com/zh-HK/news/277401406.md) | | Nine Dragons Paper Holdings (NDGPF) Receives a Buy from GF Securities | GF Securities analyst maintained a Buy rating on Nine Dragons Paper Holdings yesterday and set a price target of HK$9.87 | [Link](https://longbridge.com/zh-HK/news/277339226.md) | | Yeebo trims Nantong Jianghai stake to fund core display and AI growth | Yeebo (International Holdings) Limited has sold 9,902,000 shares in Nantong Jianghai, reducing its stake to 12.64%. The | [Link](https://longbridge.com/zh-HK/news/276909323.md) | --- > **免責聲明**：本文內容僅供參考，不構成任何投資建議。